Comparison of the safety and efficacy of the combination of Wharton's jelly mesenchymal stem cells conditioned medium and platelet-rich plasma and liposomal of Wharton's jelly mesenchymal stem cells conditioned medium and platelet-rich plasma in the treatment of androgenetic alopecia

Comparison of safety and efficacy of Wharton's jelly mesenchymal stem cells conditioned medium and Platelet-Rich Plasma (WJMSCs CM-PRP) and liposomal Wharton's jelly mesenchymal stem cells conditioned medium-Platelet-Rich Plasma (Liposomal WJMSCs CM-PRP) in androgenetic alopecia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200127046282N24

Enrollment

Registered

2023-02-18

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia. Androgenic alopecia, unspecified

Interventions

Intervention 1: Intervention group: patients will use liposomal conditioned medium-platelet rich plasma daily for three months. Intervention 2: Control group: patients will receive conditioned medium-

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Not using topical or oral medication for the treatment of alopecia during the last six months AGA type 2-4

Exclusion criteria

Exclusion criteria: Age under18 years pregnancy breastfeeding History of malignant diseases Taking any topical or systemic treatment during the study

Design outcomes

Primary

Measure	Time frame
Hair density. Timepoint: Before starting the treatment, the end of the first, second, third month and one month after the end of the treatment period (end of the fourth month). Method of measurement: Biometric examination will be done and the findings from VISIOFACE and TES-TB (hair loss type with X1 lens, hair density and scalp condition with X60Triple lens, hair diameter and PORE condition with KPL X150 lens and hair shaft surface condition with X700 lens) It will be recorded for each patient.	—

Measure

Time frame

Hair density. Timepoint: Before starting the treatment, the end of the first, second, third month and one month after the end of the treatment period (end of the fourth month). Method of measurement: Biometric examination will be done and the findings from VISIOFACE and TES-TB (hair loss type with X1 lens, hair density and scalp condition with X60Triple lens, hair diameter and PORE condition with KPL X150 lens and hair shaft surface condition with X700 lens) It will be recorded for each patient.

—

Secondary

Measure	Time frame
Side effects. Timepoint: One week after session. Method of measurement: Questionnaire and visit.;Satisfaction. Timepoint: One months after the last session. Method of measurement: Satisfaction Questionnaire and visit.;Tolerability. Timepoint: Each session after transplantation. Method of measurement: Questionnaire and visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026